NuCana (NCNA) Other Non-Current Liabilities (2017 - 2025)
NuCana (NCNA) reported Other Non-Current Liabilities of $77149.6 for Q4 2025, up 50.27% on a YoY basis from $51340.1 in Q4 2024, and down 1.42% sequentially from $78263.0 in Q3 2025.
NuCana (NCNA) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Other Non-Current Liabilities data on file, last reported at $77149.6 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 50.27% year-over-year to $77149.6; the trailing twelve-month figure through Dec 2025 stood at $77149.6 (up 50.27% YoY), and the FY2025 full-year result was $76473.6, up 49.56% from the prior year.
- Other Non-Current Liabilities declined to $77149.6 in Q4 2025, from $78263.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 million in Q1 2023 to a low of $38979.0 in Q3 2024.
- A 5-year average of $729175.5 and a median of $68141.2 in 2023 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities jumped 7883.35% in 2023 and slumped 98.51% in 2024, its largest moves.
- Tracing NCNA's Other Non-Current Liabilities over 5 years: stood at $62008.5 in 2021, then jumped by 7655.4% to $4.8 million in 2022, then slumped by 98.5% to $71986.8 in 2023, then decreased by 28.68% to $51340.1 in 2024, then jumped by 50.27% to $77149.6 in 2025.
- Business Quant data shows NCNA's Other Non-Current Liabilities at $77149.6 in Q4 2025, $78263.0 in Q3 2025, and $77374.6 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 77,149.64 |
| Sep 30, 2025 | 78,263.00 |
| Jun 30, 2025 | 77,374.65 |
| Mar 31, 2025 | 50,380.02 |
| Dec 31, 2024 | 51,340.07 |
| Sep 30, 2024 | 38,979.00 |
| Jun 30, 2024 | 73,208.80 |
| Mar 31, 2024 | 73,574.05 |
| Dec 31, 2023 | 71,986.81 |
| Sep 30, 2023 | 73,467.72 |
| Jun 30, 2023 | 3.75 Mn |
| Mar 31, 2023 | 4.93 Mn |
| Dec 31, 2022 | 4.81 Mn |
| Sep 30, 2022 | 54,213.22 |
| Jun 30, 2022 | 57,928.45 |
| Mar 31, 2022 | 61,724.44 |
| Dec 31, 2021 | 62,008.49 |
| Sep 30, 2021 | 63,414.83 |
| Jun 30, 2021 | 64,295.50 |
| Mar 31, 2021 | 63,430.36 |